Publicaciones en colaboración con investigadores/as de Sarah Cannon Research Institute (2)

2024

  1. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 588-602

2019

  1. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial

    Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2825-2834